BACKGROUND: @entity56 ( @entity56 ) to @entity902 -based chemotherapies are increasingly being recognized. The authors developed a novel risk-stratification protocol that was used successfully in a small number of @entity1 with @entity3003 -induced @entity56 . OBJECTIVE: To describe the utility of this protocol in a large number of @entity1 with @entity3003 - or @entity901 -induced @entity56 . METHODS: A 5-year retrospective review of @entity1 referred to Massachusetts General Hospital with @entity3003 - or @entity901 -induced HSR was performed. @entity1 were managed using a risk-stratification protocol using 3 repeat skin tests (STs) with intervening desensitizations. If the repeat ST result remained negative 3 times, @entity1 received subsequent infusions without desensitization. RESULTS: From 2008 to 2012, 142 @entity1 (92 treated with @entity3003 , 50 treated with @entity901 ) completed 574 desensitizations. Most @entity1 were @entity1 (84.5%, mean    SD 58.1    9.3 years). @entity1 with @entity3003 -induced @entity56 were classified as having positive (n  = 32, 34.8%), negative (n  = 38, 41.3%), or converted (n  = 22, 23.9%) ST reactions when the initial negative ST reaction converted to positive at repeat ST. Of those with @entity901 -induced @entity56 , 22 (44%) had positive, 25 (50%) had negative, and 3 (6%) had converted ST reactions. Of the @entity1 with negative ST reactions, 17 with @entity3003 -induced @entity56 and 16 with @entity901 -induced @entity56 safely completed 59 and 95 outpatient infusions, respectively, without desensitizations. For @entity3003 and @entity901 , ST conversion was associated with an interval of at least 6 months from the HSR to the initial ST ( @entity3003 , P  = .002; @entity901 , P  = .045). CONCLUSION: This risk-stratification protocol for presumed @entity3003 - and @entity901 -induced @entity56 safely identifies false-negative ST reactions and nonallergic @entity1 who can receive infusions without desensitizations. This leads to fewer unnecessary desensitizations and improved @entity1 care.

Risk-stratification protocol for @entity3003 and @entity901 XXXX : repeat skin testing to identify drug allergy.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity56 :: ('MESH:D004342', 'Disease') :: ['HSRs', 'Hypersensitivity reactions'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity56 :: (MESH:D004342,Disease) :: ['hypersensitivity']
